Linked Life Data

18047849

Source:http://linkedlifedata.com/resource/pubmed/id/18047849

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11 A
pubmed:dateCreated
2007-11-30
pubmed:abstractText
Our purpose is to review recent research in the area of high-density lipoprotein (HDL) cholesterol raising and coronary artery disease (CAD) risk reduction. It is known that a decreased HDL cholesterol level is an important CAD risk factor and that raising HDL cholesterol has been associated with CAD risk reduction. A relative new strategy for raising HDL cholesterol, inhibition of cholesteryl ester transfer protein (CETP), is markedly effective. CETP inhibitors prevent the transfer of cholesteryl ester from HDL to triglyceride-rich lipoproteins in exchange for triglyceride. One inhibitor, torcetrapib, binds to CETP on HDL, markedly increases HDL cholesteryl ester, has no effect on fecal cholesterol excretion, but can raise blood pressure. A large clinical trial in patients with CAD who were taking atorvastatin was recently stopped prematurely because of excess mortality in those receiving torcetrapib versus placebo, and 2 other trials reported no benefit of torcetrapib on coronary atherosclerosis or carotid intima-media thickness as compared with subjects on atorvastatin alone. The adverse effects of torcetrapib may be compound specific, and because the crystal structure of CETP is now known, it should be possible to develop more optimal CETP inhibitors that do not form a nonproductive complex with CETP on the HDL particle, as has been reported for torcetrapib. Another alternative for increasing HDL levels is to develop more effective and better tolerated niacin preparations.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
3
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
n25-31
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
pubmed:affiliation
Cardiovascular Research and Lipid Metabolism Laboratories, Tufts University, Boston, Massachusetts 02111, USA. ernst.schaefer@tufts.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't